CONNECT WITH US
HealthTech

HealthTech

Danaher’s Cepheid business to lay off 67 people in California

MedTech Dive logo

Published on

Add as a preferred source on Google
Danaher’s Cepheid business to lay off 67 people in California

The job cuts at Danaher’s molecular diagnostics subsidiary will take place by the end of the year and affect mostly scientists and engineers, according to a state filing.

Danaher’s Cepheid molecular diagnostics subsidiary plans to lay off 67 people in California, according to a Worker Adjustment and Retraining Notification letter filed with the state.

The layoffs affect employees at the company’s facility in Sunnyvale, California, and are expected to take place by Dec. 28. Most of those whose jobs are being cut hold positions as scientists and engineers, according to the WARN notice. Five of the employees work remotely.

A company representative did not identify a specific catalyst for the job cuts when asked by MedTech Dive. “These actions are part of regular business planning and will help ensure we remain agile and competitive in a rapidly evolving healthcare landscape,” the representative said in an email.

Cepheid, whose headquarters are in Sunnyvale, is part of Danaher’s diagnostics segment. Danaher acquired the business in 2016 for about $4 billion. Danaher is projecting flat core diagnostics revenue growth, excluding respiratory testing, in fiscal 2026, after reporting core diagnostics revenue growth of 1.5% in 2025.

Cepheid last year notified California of plans to reduce its workforce by 167 positions at sites across the state, including Sunnyvale. The subsidiary laid off more than 1,300 people in California in 2023 and 2024, as sales of respiratory tests declined after the COVID-19 pandemic.



Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.